Therefore, suppression of hepatic p300 activity may be useful target for the treatment of hepatic steatosis and pharmacological p300 blockers may represent a potential option for NAFLD treatment. This evidence concerns the gene EP300 and metabolic dysfunction-associated steatotic liver disease.